Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI).
Ernstoff describes the 2:1 randomization of this phase II study. He mentions that management of toxicities is still in development, but they immediately stop treatment when autoimmune toxicities occur.
Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma receiving nivolumab combined with ipilimumab.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More